Regeneron up on earnings

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gained $22.51 to $326.52 on Tuesday after reporting 4Q13 and 2013 revenues that beat the Street and introducing 2014 sales guidance for ophthalmic drug Eylea aflibercept. For the quarter, the company reported revenues of $610.4 million, beating the Street's $580.5 million estimate and up 47% from $414.6 million in 4Q12. U.S. sales of Eylea were $402 million in the quarter, up from $276 million in 4Q12. Regeneron's partner Bayer AG (Xetra:BAYN) recorded ex-U.S. Eylea sales of $184 million in 4Q13. Non-GAAP diluted EPS in the quarter were $2.24, up from $1.47 in 4Q12 and beating the Street's estimate of $2.07-$2.09. ...